<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JPP</journal-id>
<journal-id journal-id-type="hwp">spjpp</journal-id>
<journal-title>Journal of Pharmacy Practice</journal-title>
<issn pub-type="ppub">0897-1900</issn>
<issn pub-type="epub">1531-1937</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0897190012465950</article-id>
<article-id pub-id-type="publisher-id">10.1177_0897190012465950</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Anticoagulant Use in Real Time</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>Divyamani</given-names>
</name>
<degrees>PhD, RPh</degrees>
<xref ref-type="aff" rid="aff1-0897190012465950">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Watzak</surname>
<given-names>Bree</given-names>
</name>
<degrees>PharmD, BCPS</degrees>
<xref ref-type="aff" rid="aff2-0897190012465950">2</xref>
<xref ref-type="corresp" rid="corresp1-0897190012465950"/>
</contrib>
</contrib-group>
<aff id="aff1-0897190012465950">
<label>1</label>Pearland, TX, USA </aff>
<aff id="aff2-0897190012465950">
<label>2</label>Department of Pharmacy Practice, Texas A&amp;M University, Kingsville, TX, USA</aff>
<author-notes>
<corresp id="corresp1-0897190012465950">Bree Watzak, Texas A&amp;M University, SRPH Administration Bldg, University Drive &amp; Adriance Lab Road MS 1266, College Station, Kingsville, TX 77843, USA Email: <email>watzak@pharmacy.tamhsc.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>26</volume>
<issue>3</issue>
<issue-title>Pharmacy Practice I</issue-title>
<fpage>270</fpage>
<lpage>279</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). Each year, VTE affects about 300 000 to 600 000 people in the United States, and death is the first manifestation in one-fourth of this population.<sup>1</sup>{Beckman, 2010 #79} Moreover, approximately 10% of the US population has genetic factors that increase their risk for developing thrombosis.<sup>1</sup> In addition to inherited disorders, factors that contribute to VTE include prolonged immobilization, trauma, surgery, cancer, and critically ill patients.<sup>2</sup> Routine assessment and prophylaxis are recommended in these groups to avoid DVT-related complications.<sup>2</sup> Anticoagulants are the mainstay of drugs used in DVT/PE prevention and treatment. Despite the availability of evidence-based guidelines for anticoagulant therapy, there is suboptimal implementation of DVT prophylaxis in hospitalized patients.<sup>3</sup> All anticoagulants are “high-alert” drugs, and judicious use is mandatory to prevent bleeding complications.<sup>4</sup> This review discusses treatment guidelines, monitoring, side effects, and reversal agents available for some anticoagulant drugs approved for VTE. Dissemination of the knowledge via pharmacy education programs significantly improves the adherence to VTE prophylaxis.<sup>5</sup> Understanding the clinical aspects of anticoagulant dispensing as presented in this review is hoped to facilitate implementation of the theoretical knowledge as well as evidence-based guidelines in order to maximize patient benefit.</p>
</abstract>
<kwd-group>
<kwd>anticoagulant</kwd>
<kwd>heparin</kwd>
<kwd>DVT</kwd>
<kwd>PE</kwd>
<kwd>atrial fibrillation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>This perspective shall focus on some key practical aspects of anticoagulant dispensing and monitoring. Pharmacy schools and assessment methods of state pharmacy boards rigorously test a student’s knowledge. Moreover, evidence-based guidelines are periodically published in order to assist clinicians and pharmacists in optimizing anticoagulant use in patients.<sup>
<xref ref-type="bibr" rid="bibr6-0897190012465950">6</xref>
</sup> However, in some instances, there is a gap between practical knowledge afforded by experience and knowledge derived from books. This article is aimed at bridging some of this gap with respect to anticoagulant dispensing. In order to put experience and information in perspective, each section begins with a brief summary of the anticoagulant class. Extensive details about signaling pathways and mechanisms covered in the pharmacology books have been omitted.<sup>
<xref ref-type="bibr" rid="bibr7-0897190012465950">7</xref>
<xref ref-type="bibr" rid="bibr8-0897190012465950"/>
<xref ref-type="bibr" rid="bibr9-0897190012465950"/>–<xref ref-type="bibr" rid="bibr10-0897190012465950">10</xref>
</sup> The focus of this article is practical/real-life experience. Finally, as a pharmacist, one encounters patients who fall in the “gray” area, where one needs to use clinical discretion. These scenarios can be challenging and at the same time offer a great learning experience. Such thought-provoking clinical case studies have been presented throughout this article, and each case is discussed in the <xref ref-type="app" rid="app1-0897190012465950">Appendix</xref> section. Anticoagulants are considered high-alert medications and about 50 000 people per year experience fatal bleeding from anticoagulant use.<sup>
<xref ref-type="bibr" rid="bibr4-0897190012465950">4</xref>,<xref ref-type="bibr" rid="bibr11-0897190012465950">11</xref>
</sup> Hence, pharmacists have a crucial role in ensuring safety and efficacy of anticoagulant use in patients.</p>
<sec id="section1-0897190012465950">
<title>Brief Summary of Anticoagulants</title>
<p>Anticoagulants are a class of drugs used to prevent clot formation in disease states, that is, stroke, heart disease, atrial fibrillation, and deep vein thrombosis (DVT)/pulmonary embolism (PE).<sup>
<xref ref-type="bibr" rid="bibr9-0897190012465950">9</xref>
</sup> Coagulation or clot formation involves 2 distinct processes—a physical process involving platelet aggregation and a chemical process that involves clotting factors (<xref ref-type="fig" rid="fig1-0897190012465950">Figure 1</xref>).<sup>
<xref ref-type="bibr" rid="bibr12-0897190012465950">12</xref>
</sup> Agents that inhibit the physical process are termed antiplatelet drugs and act by inhibiting thromboxane A2 (eg, aspirin) or inhibiting activation of glycoprotein receptor complex IIb/IIIa (eg, clopidogrel, eptifibatide, abciximab, and tirofiban).<sup>
<xref ref-type="bibr" rid="bibr12-0897190012465950">12</xref>
</sup> Anticoagulants, on the other hand, inhibit the chemical process of clot formation by acting on clotting factors.<sup>
<xref ref-type="bibr" rid="bibr12-0897190012465950">12</xref>
</sup> The unifying side effect observed in all the anticoagulants is the varying degree of bleeding risk. Thus, known or overt bleeding is an absolute contraindication for treatment with anticoagulants and monitoring is a critical component of the anticoagulant therapy. However, menses and hemorrhoidal bleeding are not considered contraindications.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012465950">13</xref>
</sup> Understanding the key anticoagulant drug classes becomes easier by reflecting upon the primary steps in coagulation.<sup>
<xref ref-type="bibr" rid="bibr10-0897190012465950">10</xref>
</sup> Coagulation occurs by 2 pathways: intrinsic pathway and extrinsic pathway. Both pathways involve the stepwise activation of “factors,” the majority of which are serine proteases. Activation of coagulation pathways converge in the activation of factor Xa, which in turn activates thrombin. These pathways culminate in the formation of a clot (fibrin polymer) by activating fibrinogen.<sup>
<xref ref-type="bibr" rid="bibr10-0897190012465950">10</xref>,<xref ref-type="bibr" rid="bibr14-0897190012465950">14</xref>
</sup> In order to prevent excess clotting, a mechanism comprising tissue plasminogen activator (tPA) functions to dissolve the clots. The tPA converts plasminogen to plasmin, which in turn degrades fibrin (<xref ref-type="fig" rid="fig1-0897190012465950">Figure 1</xref>). Hence, the risk of certain clotting conditions such as venous thromboembolism (VTE) can be increased when the homeostatic balance between clotting and fibrin lysis is tipped in favor of coagulation.<sup>
<xref ref-type="bibr" rid="bibr15-0897190012465950">15</xref>
</sup> A highly purified form of cellular tPA, alteplase (Activase), is useful as a thrombolytic agent for the treatment of ischemic strokes if administered within 4.5 hours after the onset of stroke symptoms.<sup>
<xref ref-type="bibr" rid="bibr16-0897190012465950">16</xref>
</sup>
</p>
<fig id="fig1-0897190012465950" position="float">
<label>Figure 1.</label>
<caption>
<p>Key coagulation players and anticoagulant mechanism of action. Chemical and physical arms of the coagulation process include clotting factors and platelets, respectively. The chemical arm is further divided into extrinsic pathway and intrinsic pathway starting with the activation of factor VII and factor XII, respectively. Sites of inhibition by anticoagulant drugs are represented using a line with circular head.</p>
</caption>
<graphic xlink:href="10.1177_0897190012465950-fig1.tif"/>
</fig>
<p>Let us now examine the main classes of anticoagulants and their mechanisms of action (<xref ref-type="fig" rid="fig1-0897190012465950">Figure 1</xref>).
<list list-type="simple">
<list-item>
<p>Heparin and its derivatives: this class includes (1) unfractionated heparin (UFH), (2) low-molecular-weight heparins (LMWHs), for example enoxaparin (Lovenox), tinzaparin (Innohep), and dalteparin (Fragmin), and (3) synthetic heparin derivatives, for example fondaparinux (Arixtra). The anticoagulant effect of UFH is primarily mediated by antagonizing factor Xa and potentiating the activity of antithrombin (thrombin antagonist; <xref ref-type="fig" rid="fig1-0897190012465950">Figure 1</xref>).</p>
</list-item>
<list-item>
<p>Vitamin K antagonist (VKA): this class consists of warfarin (Coumadin) that prevents the regeneration of vitamin K reductase and hence blocks the production of vitamin K-dependent factors II, VII, IX, and X.</p>
</list-item>
<list-item>
<p>Direct thrombin inhibitors: this class includes injectable agents such as argatroban (Acova), lepirudin (Refludan), and bivalirudin (Angiomax) as well as the oral agent, dabigatran (Pradaxa).</p>
</list-item>
<list-item>
<p>Factor Xa inhibitor: rivaroxaban (Xarelto) is the only oral agent in this class available in the United States at the time of this submission.</p>
</list-item>
</list>
</p>
<p>The DVT/VTE prophylaxis is recommended in certain groups of acutely ill patients who are hospitalized and are susceptible to developing clots. This group includes patients with congestive heart disease, respiratory disease, those with restricted or no mobility (eg, majority of the patients in critical care units) as well as patients who are obese or overweight.<sup>
<xref ref-type="bibr" rid="bibr17-0897190012465950">17</xref>
</sup> It is noteworthy that in patients undergoing major orthopedic surgery, lack of anticoagulant prophylaxis can increase the DVT risk from 40% to 60%.<sup>
<xref ref-type="bibr" rid="bibr18-0897190012465950">18</xref>
</sup> The American College of Chest Physicians (ACCP) provides guidelines for stratification of patients based on the VTE risk.<sup>
<xref ref-type="bibr" rid="bibr18-0897190012465950">18</xref>,<xref ref-type="bibr" rid="bibr19-0897190012465950">19</xref>
</sup> This is a valuable tool for pharmacists and other health care personnel to ensure patients receive optimal anticoagulant therapy.</p>
</sec>
<sec id="section2-0897190012465950">
<title>Unfractionated Heparin</title>
<p>Our body is endowed with two circulating anticoagulant proteins, namely, antithrombin (AT) and heparin cofactor II (HCII).<sup>
<xref ref-type="bibr" rid="bibr12-0897190012465950">12</xref>
</sup> However, their anticoagulant efficacy under physiological conditions is poor. The glycosaminoglycan, heparin, which is present in the mast cell secretory granules, activates AT upon release. Binding of heparin significantly increases the affinity of antithrombin for thrombin, thus inhibiting thrombin and clot formation.<sup>
<xref ref-type="bibr" rid="bibr12-0897190012465950">12</xref>
</sup> This forms the basis of the anticoagulant action of heparin. Two properties make treatment with UFH highly variable. (1) Heparin is highly heterogeneous and its molecular weight can vary from 5000 to 50 000 Da. This variance in molecular weight translates to significant inconsistency in anticoagulant activity as well as pharmacokinetic profile<sup>
<xref ref-type="bibr" rid="bibr12-0897190012465950">12</xref>,<xref ref-type="bibr" rid="bibr20-0897190012465950">20</xref>
</sup> (2) In addition to AT, heparin binds to a myriad of extracellular matrix proteins (notably thrombin, tPA, and plasminogen activator inhibitor), growth factors, and inflammatory proteins (eg, platelet factor 4).<sup>
<xref ref-type="bibr" rid="bibr21-0897190012465950">21</xref>
</sup> This presents difficulties in achieving a predictable dose–response and causes variability in the degree of adverse events (eg, thrombocytopenia caused by binding to platelet factor 4). Heparin for medical use is isolated from porcine and bovine sources.</p>
<sec id="section3-0897190012465950">
<title>Dosing</title>
<p>Unfractionated heparin is used for DVT prophylaxis at a dose of 5000 units every (Q) 8 hours or Q12 hours. For the treatment of VTE, heparin is initiated at a dose of either 80 units/kg or 5000 units intravenous (IV) bolus, followed by an infusion at the rate of 18 units/kg/h or 1300 units/h, with an anti-factor Xa level of 0.3 to 0.7 unit/mL.<sup>
<xref ref-type="bibr" rid="bibr22-0897190012465950">22</xref>
</sup> When empiric dosing is employed, the maximum bolus dose and infusion rate of UFH are 5000 units and 1300 units/h, respectively.<sup>
<xref ref-type="bibr" rid="bibr22-0897190012465950">22</xref>
</sup> The activated partial thromboplastin time (aPTT) levels are monitored every 6 hours until therapeutic × 2 consecutive levels and then tapered to 24-hour monitoring. For the treatment of acute coronary syndrome (ACS), heparin bolus is initiated with 60 units/kg bolus (maximum 4000 units) and then infused at 12 units/kg/h with a goal antifactor Xa level of 0.3 to 0.7 unit/mL.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012465950">13</xref>,<xref ref-type="bibr" rid="bibr22-0897190012465950">22</xref>
</sup>
</p>
</sec>
<sec id="section4-0897190012465950">
<title>Monitoring</title>
<p>As discussed above, the UFH binds to a myriad of signaling molecules resulting in unpredictable pharmacodynamics/kinetic responses.<sup>
<xref ref-type="bibr" rid="bibr21-0897190012465950">21</xref>
</sup> Hence, when used for DVT/PE treatment, monitoring of the UFH activity is essential to ensure optimal response. The UFH activity is monitored using factor Xa assays. Of the multitude of signaling molecules it binds, heparin has the highest affinity for antithrombin.<sup>
<xref ref-type="bibr" rid="bibr21-0897190012465950">21</xref>
</sup> Upon binding, the heparin–antithrombin complex inactivates several cofactors. The cofactors most responsive to inhibition by this complex are factors IXa, Xa, and thrombin. Thus, estimation of factor Xa levels is used as a “readout” for the UFH activity.<sup>
<xref ref-type="bibr" rid="bibr20-0897190012465950">20</xref>
</sup> A decrease in the plasma factor Xa levels correlates with an increase in the UFH function. In addition, some facilities use aPTT to evaluate the anticoagulant activity of UFH if anti-Xa monitoring is not available. The aPTT tests have been widely used to monitor UFH activity for over three decades.<sup>
<xref ref-type="bibr" rid="bibr23-0897190012465950">23</xref>
</sup> Although cost effective and amenable to automation, these tests suffer from several drawbacks.<sup>
<xref ref-type="bibr" rid="bibr24-0897190012465950">24</xref>,<xref ref-type="bibr" rid="bibr25-0897190012465950">25</xref>
</sup> For example, the prolongation of aPTT time can result from factors independent of heparin activity such as presence of coagulation inhibitors. Moreover, test results are affected by various factors such as the aPTT method used for testing, type/lot of reagent used, and the instrument employed for measurement.<sup>
<xref ref-type="bibr" rid="bibr23-0897190012465950">23</xref>
</sup> Hence, aPTT test values need to be standardized for each laboratory.<sup>
<xref ref-type="bibr" rid="bibr23-0897190012465950">23</xref>
</sup> The anti-Xa assay on the other hand is more specific as it measures the activity of factor Xa alone and more closely correlates with the heparin activity. The disadvantages of this assay are its higher cost and limited availability in hospitals.<sup>
<xref ref-type="bibr" rid="bibr23-0897190012465950">23</xref>
</sup>
</p>
</sec>
<sec id="section5-0897190012465950">
<title>Heparin-Induced Thrombocytopenia</title>
<p>As discussed above, heparin interacts with diverse classes of cellular signaling molecules ranging from inflammatory mediators to growth factors.<sup>
<xref ref-type="bibr" rid="bibr21-0897190012465950">21</xref>
</sup> Heparin interacts with platelet factor 4 resulting in a heparin–platelet factor 4 complex on the surface of platelets. This complex is recognized by immunoglobulin (Ig) G resulting in platelet activation and an increased risk of venous and arterial thrombosis.<sup>
<xref ref-type="bibr" rid="bibr26-0897190012465950">26</xref>,<xref ref-type="bibr" rid="bibr27-0897190012465950">27</xref>
</sup> The exact mechanism resulting in increased thrombin generation following platelet activation is unknown. The occurrence of heparin-induced thrombocytopenia (HIT) is influenced by a number of factors, including heparin type, patient characteristics, duration of heparin therapy, and type of surgery.<sup>
<xref ref-type="bibr" rid="bibr27-0897190012465950">27</xref>
</sup> The risk of HIT is lower in patients taking LMWH relative to UFH.<sup>
<xref ref-type="bibr" rid="bibr27-0897190012465950">27</xref>
</sup> The diagnosis of HIT is made by a combination of the 4Ts scoring system and laboratory detection of HIT antibodies.<sup>
<xref ref-type="bibr" rid="bibr27-0897190012465950">27</xref>
</sup> The 4Ts represent the extent of thrombocytopenia (percentage fall in platelet count), timing of the onset of thrombocytopenia, manifestation of thrombosis symptoms, and presence of other factors <sup>
<xref ref-type="bibr" rid="bibr28-0897190012465950">28</xref>
</sup>contributing to thrombocytopenia (<xref ref-type="table" rid="table1-0897190012465950">Table 1</xref>). A low score (0-3) indicates low risk of HIT, a score of 4 to 5 suggests moderate risk, and a high score (6-8) indicates high risk of HIT.<sup>
<xref ref-type="bibr" rid="bibr28-0897190012465950">28</xref>
</sup> A high score warrants discontinuation of heparin and use of alternative therapies such as argatroban.<sup>
<xref ref-type="bibr" rid="bibr27-0897190012465950">27</xref>,<xref ref-type="bibr" rid="bibr28-0897190012465950">28</xref>
</sup> <xref ref-type="table" rid="table1-0897190012465950"/>
</p>
<table-wrap id="table1-0897190012465950" position="float">
<label>Table 1.</label>
<caption>
<p>4T Pretest
<sup><xref ref-type="bibr" rid="bibr28-0897190012465950">28</xref></sup>
 Scoring System for HIT<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table1-0897190012465950" xlink:href="10.1177_0897190012465950-table1.tif"/>
<table>
<thead>
<tr>
<th>Thrombocytopenia </th>
<th>Platelet Count Fall Timing</th>
<th>Thrombosis</th>
<th>Other Causes of Thrombocytopenia</th>
</tr>
</thead>
<tbody>
<tr>
<td>For platelet count fall &gt;50% and nadir ≤20; score = 2</td>
<td>Onset day: 5-10; score = 2</td>
<td>New thrombosis; score = 2</td>
<td>No apparent alternate cause; score = 2</td>
</tr>
<tr>
<td>For platelet count fall between 30% and 50% or nadir 10-19; score = 1</td>
<td>Day of platelet fall unclear due to missing counts, score = 1</td>
<td>Recurrent thrombosis or suspected thrombosis; score = 1</td>
<td>Possible alternate cause; score = 1</td>
</tr>
<tr>
<td>For platelet count fall &lt;30% or nadir &lt;10; score = 0</td>
<td>Day of fall &lt; 4 days in absence of recent exposure</td>
<td>None; score = 0</td>
<td>Definite alternate cause; score = 0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0897190012465950">
<p>Abbreviation: HIT, heparin-induced thrombocytopenia; TCP, thrombocytopenia.</p>
</fn>
<fn id="table-fn2-0897190012465950">
<p>
<sup>a </sup>The 4T scoring system evaluates the probability that a patient’s thrombocytopenia has resulted from heparin administration. A high 4T score correlates with greater likelihood that TCP is heparin-mediated. Final confirmation of HIT is however based on laboratory testing for HIT antibodies.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-0897190012465950">
<title>Heparin Reversal</title>
<p>The anticoagulant effects of UFH and to a lesser extent LMWH can be reversed using the positively charged peptide, protamine sulfate. Protamine is administered at a dose of 1 mg IV for every 100 units of heparin and given over 1 to 3 minutes. The maximum infusion rate should not exceed 50 mg every 10 minutes and subsequent doses of protamine are evaluated by monitoring aPTT every 5 to 15 minutes.</p>
</sec>
</sec>
<sec id="section7-0897190012465950">
<title>Low-Molecular-Weight Heparins</title>
<p>LMWHs are obtained by the depolymerization of UFH by chemical or biochemical methods and their average molecular weight ranges from 4 to 6 kDa.<sup>
<xref ref-type="bibr" rid="bibr12-0897190012465950">12</xref>
</sup> The smaller size of LMWHs translates to less variability in dose–response compared to UFH and fewer nonspecific interactions.<sup>
<xref ref-type="bibr" rid="bibr12-0897190012465950">12</xref>
</sup> Hence, compared to UFH, the LMWHs have a higher margin of safety and a lower risk of inducing HIT. In addition, the longer half-life and better pharmacokinetic profile of LMWHs circumvent the need for frequent laboratory monitoring.<sup>
<xref ref-type="bibr" rid="bibr12-0897190012465950">12</xref>,<xref ref-type="bibr" rid="bibr29-0897190012465950">29</xref>
</sup> Another feature that distinguishes LMWHs from UFH is that the former has greater binding affinity/inhibitory effect on factor Xa relative to thrombin.<sup>
<xref ref-type="bibr" rid="bibr29-0897190012465950">29</xref>
</sup>
</p>
<p>LMWHs, primarily enoxaparin (Lovenox) and dalteparin (Fragmin), are broadly used in hospitalized patients for the purpose of DVT prophylaxis or treatment of DVT or stroke prevention in atrial fibrillation (A-fib).<sup>
<xref ref-type="bibr" rid="bibr30-0897190012465950">30</xref>
</sup> Another LMWH, tinzaparin (Innohep), is Food and Drug Administration (FDA) approved for the treatment of DVT.<sup>
<xref ref-type="bibr" rid="bibr30-0897190012465950">30</xref>
</sup> The two primary LMWHs are shown to be equally effective for the prophylaxis/treatment post hip and abdominal surgery; however, dalteparin is the only LMWH approved for VTE treatment in patients with cancer.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012465950">13</xref>,<xref ref-type="bibr" rid="bibr31-0897190012465950">31</xref>
</sup> In addition to its application in the prophylaxis and treatment of DVT/PE, A-fib, stroke, and so on, enoxaparin is used as bridge therapy for patients requiring long-term anticoagulation with warfarin, as the latter has a delayed onset of action (about 5 days).</p>
<p>Since enoxaparin is eliminated by the kidneys, renal dysfunction warrants dose reduction. Another parameter to consider prior to dispensing enoxaparin is platelet count. Like UFH, LMWH can cause thrombocytopenia and this risk is increased in patients with a history of HIT. Hence, in patients with confirmed HIT, it is recommended to use nonheparin-based alternatives such as fondaparinux, argatobran, bivalirudin, and lepirudin over enoxaparin (grade 1C).<sup>
<xref ref-type="bibr" rid="bibr32-0897190012465950">32</xref>
</sup> The manufacturer recommends holding enoxaparin<sup>
<xref ref-type="bibr" rid="bibr33-0897190012465950">33</xref>
</sup> for a platelet count of less than 100 000 cells/mm<sup>3</sup>. However, individual hospitals may have their own cutoff limit.</p>
<sec id="section8-0897190012465950">
<title>Dosing</title>
<p>The recommended DVT prophylaxis dose of enoxaparin is 40 mg once daily (creatinine clearance [CrCl]<sup>
<xref ref-type="bibr" rid="bibr34-0897190012465950">34</xref>
</sup>  &gt;30 mL/min, which is calculated using Cockroft-Gault equation) or 30 mg subcutaneously OD (CrCl &lt; 30 mL/min).<sup>
<xref ref-type="bibr" rid="bibr6-0897190012465950">6</xref>
</sup> In patients undergoing hip/knee surgery, the prophylactic dose of enoxaparin is 30 mg Q12 h. Enoxaparin is used at a dose of 1 mg/kg Q12 h for the treatment of DVT and myocardial infarction (MI). An OD dosing option of 1.5mg/kg/d is also available for DVT treatment. As is the case with prophylaxis, treatment doses of enoxaparin need to be adjusted based on the patient’s renal function. For CrCl &gt; 30 mL/min, doses of 1 mg/kg Q12 are used, and this dose is decreased to 1 mg/kg/d for CrCl &lt; 30 mL/min.</p>
<p>Enoxaparin is not FDA approved for patients undergoing hemodialysis and sufficient studies to warrant use in this population are not available.<sup>
<xref ref-type="bibr" rid="bibr35-0897190012465950">35</xref>
</sup> In these patients, UFH is an effective alternative at a dose of 5000 units subcutaneously 2 to 3 times daily. However, it is not uncommon for some medical practitioners to continue using enoxaparin even in dialysis patients.</p>
<p>For DVT prophylaxis, dalteparin is used at a dose of 5000 units subcutaneously OD.<sup>
<xref ref-type="bibr" rid="bibr17-0897190012465950">17</xref>
</sup> Unlike UFH, the anticoagulant effect of LMWHs is only partially reversed with protamine.<sup>
<xref ref-type="bibr" rid="bibr22-0897190012465950">22</xref>
</sup> Dalteparin is recommended at a dose of 100 units/kg twice a day (bid) or 200 units/kg OD for VTE treatment. In case of severe renal impairment (serum creatinine [SCr] &gt; 3× normal), dalteparin dose should be adjusted to maintain a factor Xa level of 1 unit/mL, 4 to 6 hours post first injection.<sup>
<xref ref-type="bibr" rid="bibr36-0897190012465950">36</xref>
</sup>
</p>
</sec>
<sec id="section9-0897190012465950">
<title>Monitoring</title>
<p>Unlike UFH, routine monitoring of LMWH activity is not necessary. However, in special patient populations, such as morbid obesity, pregnancy, or renal failure, where studies on appropriate dosing are not available, periodic monitoring is recommended.<sup>
<xref ref-type="bibr" rid="bibr20-0897190012465950">20</xref>
</sup> In these instances, anti-Xa levels are assessed 4 hours post-dose, with the goal anti-Xa range being 0.6 to 1 unit/mL.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012465950">13</xref>
</sup>
</p>
</sec>
<sec id="section10-0897190012465950">
<title>Reversal</title>
<p>Reversal of LMWH is accomplished using 1 mg of protamine for every milligram of enoxaparin and 1 mg protamine for every 100 anti-Xa international unit (IU) of dalteparin.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012465950">13</xref>
</sup> However, protamine is not risk free and carries a black box warning for hypersensitivity reactions.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012465950">13</xref>
</sup>
</p>
<boxed-text id="boxed-text1-0897190012465950" position="float">
<sec id="section11-0897190012465950">
<title>Box 1</title>
<p>Case 1: R.Z. is a 65-year-old female weighing 350 lbs and 5ft 5 inches tall. She is admitted to the hospital for bariatric surgery. Her recent SCr value was 1 mg/dL. The physician recommends starting R.Z. on 30 mg enoxaparin OD for DVT prophylaxis. Is this dose appropriate?</p>
</sec>
</boxed-text>
</sec>
</sec>
<sec id="section11c-0897190012465950">
<title>Synthetic Heparin (Fondaparinux)</title>
<p>Fondaparinux (arixtra) is a pentasaccharide sequence that selectively binds to antithrombin and enhances antithrombin-mediated inactivation of factor Xa and thrombin (<xref ref-type="fig" rid="fig1-0897190012465950">Figure 1</xref>). This agent is distinct from UFH and LMWH in its low molecular weight and long half-life (17-21 hours).<sup>
<xref ref-type="bibr" rid="bibr37-0897190012465950">37</xref>
</sup> Additionally, fondaparinux is a useful alternative for patients who experience HIT.<sup>
<xref ref-type="bibr" rid="bibr37-0897190012465950">37</xref>
</sup> The primary disadvantage of fondaparinux is its cost and so it is rarely a part of hospital formularies. Some hospital pharmacies require physicians to complete documentation prior to dispensing fondaparinux to justify the cost–benefit ratio. Moreover, unlike UFH and LMWH, fondaparinux cannot be reversed with protamine or any other available agents.<sup>
<xref ref-type="bibr" rid="bibr37-0897190012465950">37</xref>
</sup> This anticoagulant is used at a dose of 2.5 mg subcutaneously OD for VTE prophylaxis in patients weighing &gt;50 kg. For treatment of VTE, the dose of fondaparinux is based on the patient’s body weight (5 mg for &lt;50 kg, 7.5 mg for &lt;100 kg, and 10 mg for &gt;100 kg).<sup>
<xref ref-type="bibr" rid="bibr6-0897190012465950">6</xref>
</sup> Fondaparinux is contraindicated in patients with CrCl &lt; 30mL/min.<sup>
<xref ref-type="bibr" rid="bibr22-0897190012465950">22</xref>
</sup>
</p>
<boxed-text id="boxed-text2-0897190012465950" position="float">
<sec id="section11a-0897190012465950">
<title>Box 2</title>
<p>Case 2: A 40-year-old female is being treated for  chronic obstructive pulmonary disease (COPD). She is 5 ft 6 inches tall and weighs 300 lbs. She is started on corticosteroid therapy and a prophylactic dose of enoxaparin 40 mg/subq/d. Her  past medical history (PMH) indicates a prior DVT and she is refusing to wear sequential compression devices (SCDs) as she describes them as “uncomfortable and makes my legs taut.” Her SCr at the initiation of therapy (2 days ago) was 0.9 mg/dL but has now steadily increased to 2.4 mg/dL. Does this warrant a change in enoxaparin dose? Why or Why not?</p>
</sec>
</boxed-text>
</sec>
<sec id="section12-0897190012465950">
<title>Vitamin K Antagonists: Warfarin</title>
<p>Until recently, warfarin was the only oral anticoagulant available for stroke prophylaxis for patients with A-fib, in the outpatient setting. It acts by antagonizing the activity of vitamin K, which is essential for gamma carboxylation of glutamate residues in prothrombin.<sup>
<xref ref-type="bibr" rid="bibr9-0897190012465950">9</xref>,<xref ref-type="bibr" rid="bibr38-0897190012465950">38</xref>
</sup> Despite its convenience as an orally bioavailable anticoagulant, warfarin therapy presents several challenges, such as the need for frequent monitoring and a stumbling array of interactions with drugs, foods, and herbal supplements.<sup>
<xref ref-type="bibr" rid="bibr9-0897190012465950">9</xref>,<xref ref-type="bibr" rid="bibr38-0897190012465950">38</xref>
</sup> In addition to close monitoring, patients on warfarin need extensive counseling on the associated bleeding risks, importance of keeping international normalized ratio (INR) within the target range, and maintaining a diet consistent with the amount of vitamin K.<sup>
<xref ref-type="bibr" rid="bibr9-0897190012465950">9</xref>
</sup> Despite these drawbacks, warfarin is highly affordable and is the most frequently prescribed anticoagulant in the United States.<sup>
<xref ref-type="bibr" rid="bibr39-0897190012465950">39</xref>
</sup>
</p>
<sec id="section13-0897190012465950">
<title>Dosing</title>
<p>The recommended initial dose of warfarin for the prevention of VTE in patients with A-fib is 5 to 10 mg for 1 to 2 days followed by dose adjustment based on INR values that allow the efficacy to be evaluated.<sup>
<xref ref-type="bibr" rid="bibr17-0897190012465950">17</xref>
</sup> Recently formulated ACCP guidelines suggest initiating warfarin therapy at a dose of 10 mg in healthy patients.<sup>
<xref ref-type="bibr" rid="bibr6-0897190012465950">6</xref>
</sup> In elderly individuals, debilitated or malnourished patients as well as patients with coronary heart failure (CHF), the starting daily dose of warfarin is not to exceed 5 mg.<sup>
<xref ref-type="bibr" rid="bibr17-0897190012465950">17</xref>
</sup> As discussed above, it takes approximately 5 days to achieve therapeutic anticoagulation with warfarin. This is because although warfarin inhibits synthesis of new coagulation factors, it does not affect the stability of previously synthesized factors.<sup>
<xref ref-type="bibr" rid="bibr9-0897190012465950">9</xref>
</sup> Hence, treatment with warfarin is done in conjunction with enoxaparin. Enoxaparin is initiated at the same time as warfarin and discontinued after the target INR has been reached and remains stable for 2 consecutive days.<sup>
<xref ref-type="bibr" rid="bibr17-0897190012465950">17</xref>,<xref ref-type="bibr" rid="bibr40-0897190012465950">40</xref>
</sup>
</p>
</sec>
<sec id="section14-0897190012465950">
<title>Monitoring</title>
<p>Treatment with warfarin requires frequent monitoring. Warfarin is prescribed routinely for VTE prophylaxis in hospitalized patients undergoing hip/knee replacement surgery, and the risk for VTE is highest with major orthopedic surgery relative to other surgical procedures.<sup>
<xref ref-type="bibr" rid="bibr30-0897190012465950">30</xref>
</sup> These patients are then regularly monitored in an outpatient warfarin clinic for dose adjustments and to ensure that the goal INR is met. An important pointer prior to dispensing the first dose of warfarin is to ensure that a baseline INR has been drawn. Some hospitals have inbuilt warnings in their computerized order entry system that prohibit dispensing warfarin unless a recent INR value (recent INR: INR drawn ≤7 days ago) is available. In patients starting VKA therapy, INR monitoring is recommended after 2 to 3 doses.<sup>
<xref ref-type="bibr" rid="bibr17-0897190012465950">17</xref>
</sup> Based on the “intensity” of therapy required, the goal INR levels vary. Due to the evolving simplicity and portability of instruments used for INR measurement, the concept of “patient self-monitoring” (PSM) of anticoagulation by patients has emerged.<sup>
<xref ref-type="bibr" rid="bibr39-0897190012465950">39</xref>
</sup> This will allow patients to self-manage their anticoagulation regimen in the convenience of their home.<sup>
<xref ref-type="bibr" rid="bibr39-0897190012465950">39</xref>
</sup> Moreover, several randomized studies indicate that mortality and thromboembolic events were significantly lower in self-monitored groups relative to standard monitoring at clinics.<sup>
<xref ref-type="bibr" rid="bibr41-0897190012465950">41</xref>
<xref ref-type="bibr" rid="bibr42-0897190012465950"/>–<xref ref-type="bibr" rid="bibr43-0897190012465950">43</xref>
</sup> However, economic and functional barriers have limited the adoption of PSM and a mere 1.5% of the total population of warfarin patients participate in PSM.<sup>
<xref ref-type="bibr" rid="bibr43-0897190012465950">43</xref>,<xref ref-type="bibr" rid="bibr44-0897190012465950">44</xref>
</sup>
</p>
</sec>
<sec id="section15-0897190012465950">
<title>Reversal</title>
<p>Vitamin K is an effective antidote to reverse excessive anticoagulation by warfarin. The dose and route of vitamin K employed will depend on the INR and the presence of active bleeding. The current ACCP guidelines outline the appropriate dosing for vitamin K therapy to reverse warfarin-induced bleeding.<sup>
<xref ref-type="bibr" rid="bibr6-0897190012465950">6</xref>,<xref ref-type="bibr" rid="bibr17-0897190012465950">17</xref></sup>
</p>
<boxed-text id="boxed-text3-0897190012465950" position="float">
<sec id="section11b-0897190012465950">
<title>Box 3</title>
<p>Case 3: A 25-year-old female arrives in the emergency room complaining of severe calf muscle pain and dyspnea. She is 20 weeks pregnant. A duplex ultrasound confirms DVT. The physician on call decides to start enoxaparin therapy at 1 mg/kg Q12 hours followed by bridging therapy with warfarin. Is this the right course of action? </p>
</sec>
</boxed-text>
</sec>
</sec>
<sec id="section16-0897190012465950">
<title>Dabigatran (Pradaxa)</title>
<p>In October 2010, the FDA approved the use of an oral thrombin inhibitor, dabigatran (Pradaxa) in the United States for prevention of stroke or thromboembolism in patients with A-fib without underlying valve disease. In the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) trial, dabigatran was shown to be noninferior to warfarin (ClinicalTrials.gov identifier: NCT00262600).<sup>
<xref ref-type="bibr" rid="bibr45-0897190012465950">45</xref>
</sup> More importantly, dabigatran has much fewer drug interactions relative to warfarin and routine monitoring of INR is not required. Despite these advantages, it is critical to remember that unlike warfarin, whose effects can be readily reversed using vitamin K, reversing the effects of dabigatran is only achieved by dialysis. This presents a challenge in managing trauma in patients receiving dabigatran for stroke prophylaxis and in patients with Afib. A recent correspondence<sup>
<xref ref-type="bibr" rid="bibr46-0897190012465950">46</xref>
</sup> describes a case where lack of a pragmatic reversal strategy for dabigatran led to a patient’s neurological decay posttrauma and subsequent death. Therefore, research is underway to identify agents that can reverse dabigatran in accidental/intentional overdose and emergencies.<sup>
<xref ref-type="bibr" rid="bibr47-0897190012465950">47</xref>
</sup> Moreover, lack of a rapid reversal strategy for dabigatran precludes the use of tPA in patients who otherwise qualify to receive alteplase for ischemic stroke. This is because removal of dabigatran by dialysis is time consuming and may be difficult to complete within the 4.5-hour administration window of tPA.<sup>
<xref ref-type="bibr" rid="bibr16-0897190012465950">16</xref>,<xref ref-type="bibr" rid="bibr48-0897190012465950">48</xref>
</sup> Another challenge presented by dabigatran is the limited stability of the oral formulation. Once opened, the contents of the formulation are good only for 4 months and unit dosing by pharmacies is not recommended.<sup>
<xref ref-type="bibr" rid="bibr48-0897190012465950">48</xref>
</sup>
</p>
<p>Currently, the cost of dabigatran precludes its complete replacement of warfarin. However, dabigatran is currently being used as a “restricted” drug in many facilities. For instance, cardiologists have exclusive prescribing privileges in some hospitals; while in other centers dabigatran use is limited as a “bridge” therapy in place of enoxaparin (personal communication). The usual dose of dabigatran is 150 mg twice a day. In patients with CrCl &lt; 30 mL/min, the dose is decreased to 75 mg twice a day.<sup>
<xref ref-type="bibr" rid="bibr48-0897190012465950">48</xref>
</sup> Dabigatran is not recommended in patients with CrCl &lt; 15 mL/min.<sup>
<xref ref-type="bibr" rid="bibr48-0897190012465950">48</xref>
</sup> There are guidelines when switching a patient from warfarin or injectable anticoagulants to dabigatran: (1) when switching from warfarin to dabigatran, it is recommended to discontinue warfarin and start dabigatran when INR is &lt;2 and (2) while transitioning from subcutaneous heparin to dabigatran, the latter is initiated at the time heparin was due. The dabigatran product insert gives a complete summary of guidelines.<sup>
<xref ref-type="bibr" rid="bibr48-0897190012465950">48</xref>
</sup>
</p>
<boxed-text id="boxed-text4-0897190012465950" position="float">
<sec id="section11d-0897190012465950">
<title>Box 4</title>
<p>Case 4: A 56-year-old male is brought into the emergency room (ER) with the following symptoms: slurred speech, heartburn, and left-sided weakness. His caregiver reports that the symptoms began an hour ago when the patient was working on his yard. The pharmacist doing the medication reconciliation notes the patient is on the following drugs: Zocor 40 mg OD, Metformin 500 mg bid, Zestril 10 mg OD, Centrum 1 tab OD, and dabigatran 150 mg bid. The patient’s baseline INR = 1, hemoglobin (Hgb) = 12 g/dL, platelet (PLT) = 150 × 10<sup>3</sup> cells/mm<sup>3</sup>. His computed tomography (CT) scan confirms an ischemic stroke. Would this patient qualify to receive tPA? </p>
</sec>
</boxed-text>
</sec>
<sec id="section17-0897190012465950">
<title>Rivaroxaban (Xarelto)</title>
<p>A series of RECORD (RECORD 1, RECORD 2, and RECORD 3) trials compared the efficacy of a 10 mg OD dose of rivaroxaban with enoxaparin (40 mg subcutaneously) for prophylaxis of DVT/PE in patients undergoing hip/knee replacement surgery.<sup>
<xref ref-type="bibr" rid="bibr49-0897190012465950">49</xref>
<xref ref-type="bibr" rid="bibr50-0897190012465950"/>–<xref ref-type="bibr" rid="bibr51-0897190012465950">51</xref>
</sup> The treatment durations for hip and knee replacement surgery are 35 and 12 days, respectively. Results from these double-blind, double-dummy trials indicate that the relative risks of DVT, PE, and all-cause mortality were lower in the rivaroxaban group compared to the enoxaparin group. In addition, there was no significant increase in hemorrhage or wound complications relative to enoxaparin. Rivaroxaban is the first oral selective factor Xa inhibitor that has been FDA approved for DVT/PE prophylaxis. Moreover, in a double-blind trial, rivaroxaban was shown to be noninferior to warfarin for stroke prevention.<sup>
<xref ref-type="bibr" rid="bibr52-0897190012465950">52</xref>
</sup> Until recently, no specific antidotes were available to reverse rivaroxaban effects in accidental or intentional overdose. A recent study done in healthy volunteers showed that prothrombin complex concentrate (PCC) completely and promptly restores rivaroxaban-induced increase in prothrombin time (PT).<sup>
<xref ref-type="bibr" rid="bibr47-0897190012465950">47</xref>
</sup> Intriguingly, PCC was ineffective in reversing dabigatran.<sup>
<xref ref-type="bibr" rid="bibr47-0897190012465950">47</xref>
</sup>
</p>
</sec>
<sec id="section18-0897190012465950">
<title>Argatroban</title>
<p>This direct thrombin inhibitor is used for the prophylaxis and treatment of thrombosis in patients who have HIT. The anticoagulant effect of argatroban is measured using aPTT. The dose for prevention of HIT thrombosis is 2 mcg/kg/min, with an aPTT measured at baseline and then 2 hours after initiating the therapy with a goal aPTT of 1.5 to 3 times the initial level.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012465950">13</xref>
</sup> Argatroban is metabolized by the liver and dose adjustments are required in hepatic impairment. This agent is also FDA approved for thromboprophylaxis during PCI at a bolus dose of 350 mcg/kg followed by an infusion rate of 25 mcg/kg/min. The anticoagulant effect of argatroban is measured using aPTT. Argatroban can increase PT/INR when administered concomitantly with warfarin beyond that caused by the latter alone.<sup>
<xref ref-type="bibr" rid="bibr53-0897190012465950">53</xref>
</sup>
</p>
<boxed-text id="boxed-text5-0897190012465950" position="float">
<sec id="section11e-0897190012465950">
<title>Box 5</title>
<p>Case 5: K.J., a 50-year-old patient with health care–associated pneumonia (HCAP), is admitted to the ICU. She is intubated and the pulmonologist prescribes enoxaparin 40 mg subq OD for DVT prophylaxis. K.J. is 5 ft 10 inches tall and weighs 150 lbs. Her SCr has been stable at 1.09 mg/dL. An examination of her platelet count shows the following trend: </p>
<p>Date of test    Platelet count (×10<sup>3</sup>cells/mm<sup>3</sup>)</p>
<p>Day 1      180</p>
<p>Day 6      65</p>
<p>Day 8      45</p>
<p>What is the best course of action? </p>
</sec>
</boxed-text>
</sec>
<sec id="section19-0897190012465950">
<title>Bivalirudin</title>
<p>This agent is used for prophylaxis during percutaneous coronary intervention (PCI) in patients with HIT.<sup>
<xref ref-type="bibr" rid="bibr54-0897190012465950">54</xref>
</sup> Like argatroban, bivalirudin is a direct thrombin inhibitor. Bivalirudin decreases ischemic complications after coronary angioplasty and when used in combination with glycoprotein inhibitors in patients undergoing invasive procedures for ACS.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012465950">13</xref>,<xref ref-type="bibr" rid="bibr55-0897190012465950">55</xref>
<xref ref-type="bibr" rid="bibr56-0897190012465950"/>–<xref ref-type="bibr" rid="bibr57-0897190012465950">57</xref>
</sup>
</p>
<sec id="section20-0897190012465950">
<title>Dosing</title>
<p>Bivalirudin is initiated at a 0.75 mg/kg bolus dose immediately prior to coronary intervention procedures including PCI and percutaneous transluminal coronary angioplasty (PTCA). This rate is increased to 1.75 mg/kg/h for the duration of procedure and this may be continued up to 4 hours postprocedure if needed.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012465950">13</xref>
</sup> If further anticoagulation is needed after the initial 4-hour postprocedure infusion, the infusion may be continued at 0.2 mg/kg/h for up to an additional 20 hours.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012465950">13</xref>
</sup> For the treatment of unstable angina (UA)/ST-segment elevation myocardial infarction (NSTEMI), a bolus of 0.1 mg/kg of bivalirudin is administered followed by 0.25 mg/kg/h infusion.<sup>
<xref ref-type="bibr" rid="bibr58-0897190012465950">58</xref>
</sup> In patients with moderate- to high-risk ACS, addition of bivalirudin to glycoprotein inhibitors was noninferior to heparin.<sup>
<xref ref-type="bibr" rid="bibr59-0897190012465950">59</xref>
</sup> Dose adjustments are necessary in patients with renal impairment (CrCl &lt; 60 mL/min) and are accomplished by changing infusion rates to achieve goal aPTT levels of 1.5 to 2.5 times the baseline value.<sup>
<xref ref-type="bibr" rid="bibr54-0897190012465950">54</xref>,<xref ref-type="bibr" rid="bibr60-0897190012465950">60</xref></sup>
</p>
<boxed-text id="boxed-text6-0897190012465950" position="float">
<sec id="section11f-0897190012465950">
<title>Box 6</title>
<p>Case 6:  M.C. is a 75-year-old arthritis patient on warfarin therapy for stroke prevention. He has a PMH of recurrent A-fib. He recently switched pharmacies and upon evaluation, the new pharmacist learns that M.C. has been taking his warfarin with food. Currently, his goal INR is met. Given that warfarin interacts with food, do you think the new pharmacist should advise a change in the warfarin administration time?</p>
</sec>
</boxed-text>
</sec>
</sec>
<sec id="section21-0897190012465950">
<title>Concluding Remarks</title>
<p>Over the last several years, we have seen the arsenal of anticoagulants expand. Although the existence of multiple anticoagulants gives health care providers the opportunity to choose from a wide variety of agents, clinicians need to understand the advantages and challenges of a given anticoagulant to ensure optimal drug choice (<xref ref-type="table" rid="table2-0897190012465950">Table 2</xref>). For instance, there has been great excitement about the recent approval of the oral anticoagulant, dabigatran, as it lacks significant drug interactions observed with warfarin and eliminates the need for frequent monitoring. However, clinicians have to bear in mind that this agent lacks an antidote and hence cannot be readily reversed. In addition to limitations pertaining to drug characteristics, institution-based constraints including lack of availability of certain laboratory tests may also limit anticoagulant drug choice. Finally, patient-related factors need to be critically considered while tailoring therapy for individuals. This assessment must include the risk of bleeding versus the risk of thrombosis, comorbid conditions, concurrent medications, medication adherence, age, organ function, and even the ability to afford the prescribed medication. Clinicians have knowledge in the form of evidence-based guidelines and institutional policies at their disposal to enable in optimizing anticoagulant therapy.</p>
<table-wrap id="table2-0897190012465950" position="float">
<label>Table 2.</label>
<caption>
<p>Quick Reference Chart<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table2-0897190012465950" xlink:href="10.1177_0897190012465950-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Anticoagulant</th>
<th colspan="2">Treatment Guidelines</th>
<th rowspan="2">Monitoring</th>
<th rowspan="2">Other Clinical Notes</th>
</tr>
<tr>
<th>Prophylaxis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>UFH</td>
<td>5000 units twice a day or three times daily</td>
<td>80 units/kg or 5000 units IV bolus, infusion 18 units/kg/hr</td>
<td>Anti Factor Xa; aPTT</td>
<td>Watch for HIT; reverse using protamine</td>
</tr>
<tr>
<td>LMWH</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Enoxaparin</td>
<td>30-40 mg OD</td>
<td>1-1.5 mg/kg BID</td>
<td>No routine monitoring</td>
<td>Do not use in hemodialysis</td>
</tr>
<tr>
<td> Dalteparin</td>
<td>5000 units OD</td>
<td>100 units/kg BID or 200 units/kg OD</td>
<td>Except in special populations</td>
<td>patients due to bleeding risk</td>
</tr>
<tr>
<td>Fondaparinux</td>
<td>2.5 mg OD</td>
<td>&lt;50 kg: 5 mg &lt;100 kg: 7.5 mg &gt;100 kg: 10 mg</td>
<td>No routine monitoring</td>
<td>May be used in patients with HIT</td>
</tr>
<tr>
<td>Warfarin</td>
<td>5-10 mg initial dose, adjust based on INR</td>
<td>
</td>
<td>INR</td>
<td>Counsel on food, drug, and herbal interactions; Closely follow INR</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>150 mg twice a day when CrCl &gt; 30 mL/min; 75mg BID when Crcl&lt; 30 ml/min</td>
<td>
</td>
<td>N/A</td>
<td>Patients with ischemic stroke on dabigatran do not qualify for tPA </td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>10 mg OD</td>
<td>
</td>
<td>N/A</td>
<td>
</td>
</tr>
<tr>
<td>Argatroban</td>
<td>2 mcg/kg/min for HIT; For PCI, bolus dose of 350 mcg/kg then infuse at 25 mcg/kg/min</td>
<td>
</td>
<td>aPTT at baseline and 2 hours after procedure</td>
<td>Maybe used in patients with HIT; exercise caution in hepatic impairment</td>
</tr>
<tr>
<td>Bivalirudin</td>
<td>0.75 mg/kg bolus, infuse at 1.75 mg/kg/h</td>
<td>
</td>
<td>aPTT maybe used to optimize infusion rates</td>
<td>Dose adjustments are required in renal impairment</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0897190012465950">
<p>Abbreviations: aPTT, activated partial thromboplastin time; CrCl, creatinine clearance; HIT, heparin-induced thrombocytopenia; INR, international normalized ratio; LMWH, low-molecular-weight heparin; N/A, not applicable; OD, once daily; PCI, percutaneous coronary intervention; tPA, tissue plasminogen activator; UFH, unfractionated heparin.</p>
</fn>
<fn id="table-fn4-0897190012465950">
<p>
<sup>a </sup>This table summarizes treatment guidelines, monitoring, and other clinical notes for anticoagulants discussed in the article</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</body>
<back>
<app-group>
<app id="app1-0897190012465950">
<title>Appendix A</title>
<sec id="section23-0897190012465950">
<title>Case 1</title>
<p>R.Z.’s creatinine clearance (CrCl) based on her current serum creatinine  of 1 mg/dL = 50.5 mL/min. The American College of Chest Physicians (ACCP) guidelines recommend routine thromboprophylaxis for patients undergoing bariatric surgery.<sup>
<xref ref-type="bibr" rid="bibr6-0897190012465950">6</xref>
</sup> Given that R.Z. has good renal function and is morbidly obese, enoxaparin dose should be increased to 40 mg subcutaneously once daily. In patients undergoing bariatric surgery, prophylactic doses may be increased up to 30% and doses of 30 mg subcutaneously twice daily is optimal.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012465950">13</xref>
</sup>
</p>
</sec>
<sec id="section24-0897190012465950">
<title>Case 2</title>
<p>Patient’s CrCl at initiation of therapy is 77.8 mL/min and 2 days’ posttherapy is 29.2 mL/min (calculated using Cockroft gault equation and adjusted body weight). It is recommended to decrease enoxaparin dose to 30 mg once daily in patients with creatinine clearance &lt; 30 mL/min. However, given that this patient is morbidly obese (body mass index  = 48.5) and has a previous history of deep venous thrombosis (DVT), the risk versus benefit would favor the continuation of enoxaparin therapy for the DVT prophylaxis. However, it would be advisable to closely monitor the patient’s renal function. Alternately, subcutaneous heparin therapy may be used in place of low-molecular-weight heparin (LMWH).</p>
</sec>
<sec id="section25-0897190012465950">
<title>Case 3</title>
<p>The dosing of enoxaparin for the given condition is appropriate. For pregnant women on therapeutic LMWH, The ACCP guidelines recommend monitoring factor Xa levels (grade 1C).<sup>
<xref ref-type="bibr" rid="bibr17-0897190012465950">17</xref>
</sup> However, warfarin is a pregnancy category X and is absolutely contraindicated in pregnant women. Therefore, in this patient population, vitamin K antagonists (VKAs) are to be substituted with LMWH or unfractionated heparin (grade 1A).<sup>
<xref ref-type="bibr" rid="bibr17-0897190012465950">17</xref>
</sup>
</p>
</sec>
<sec id="section26-0897190012465950">
<title>Case 4</title>
<p>This patient is showing classic symptoms of stroke. Logically, the primary exclusion criteria for tissue plasminogen activator (tPA) administration are the presence of a hemorrhagic stroke. In this case, an ischemic stroke has been confirmed and the patient is within the 4.5-hour window for tPA administration. The blood test confirms that the international normalized ratio (INR) is within range. However, it is critical to note that the patient is on dabigatran (dabigatran does not alter the INR levels) and therefore, does not qualify to receive the tPA.</p>
</sec>
<sec id="section27-0897190012465950">
<title>Case 5</title>
<p>Several factors need to be considered while placing patients on enoxaparin that is patient’s creatinine clearance, platelet count, and dialysis status. K.J. has good creatinine clearance (66.5 mL/min calculated using the Cockroft gault equation). However, examination of her platelet count indicates a 50% drop within a 10-day period and a downward trend the following day. Although this decrease may point toward heparin-induced thrombocytopenia (HIT), it is important to confirm the diagnosis using the 4Ts score.<sup>
<xref ref-type="bibr" rid="bibr27-0897190012465950">27</xref>
</sup> K.J.’s 4Ts score:</p>
<list list-type="alpha-lower">
<list-item>
<p>Thrombocytopenia—score = 2</p>
</list-item>
<list-item>
<p>Timing—score = 2</p>
</list-item>
<list-item>
<p>Thrombosis—score = 0</p>
</list-item>
<list-item>
<p>Alternative cause hypothesis—score = 2</p>
</list-item>
</list>
<p>K.J.’s 4Ts score = 6. A score between 6 and 8 indicates a high probability of HIT. Therefore, enoxaparin must be discontinued in this patient. Sequential compression devices may be used instead for deep vein thrombosis prophylaxis. Additionally, the patient needs to be made aware and a pocket card issued in order that other health care providers can be warned of the allergy potential.<sup>
<xref ref-type="bibr" rid="bibr61-0897190012465950">61</xref>
</sup>
</p>
</sec>
<sec id="section28-0897190012465950">
<title>Case 6</title>
<p>Although warfarin has a multitude of interactions with other drugs, foods, and herbal supplements, in the case of M.C. the goal INR has been met. In other words, the warfarin dose has been optimized when patient takes the drug with food. In these instances, it is recommended to continue the current timing of warfarin administration.</p>
</sec>
</app>
</app-group>
<fn-group>
<fn fn-type="conflict" id="fn1-0897190012465950">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0897190012465950">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0897190012465950">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beckman</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Critchley</surname>
<given-names>SE</given-names>
</name>
<etal/>
</person-group> <article-title>Venous thromboembolism: a public health concern</article-title>. <source>Am J Prev Med</source>. <year>2010</year>;<volume>38</volume>(<issue>4 suppl</issue>):<fpage>S495</fpage>–<lpage>S501</lpage>.</citation>
</ref>
<ref id="bibr2-0897190012465950">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geerts</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Bergqvist</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pineo</surname>
<given-names>GF</given-names>
</name>
<etal/>
</person-group> <article-title>Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition)</article-title>. <source>Chest</source>. <year>2008</year>;<volume>133</volume>(<issue>6 suppl</issue>):<fpage>381S</fpage>–<lpage>453S</lpage>.</citation>
</ref>
<ref id="bibr3-0897190012465950">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stinnett</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Pendleton</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Skordos</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates</article-title>. <source>Am J Hematol</source>. <year>2005</year>;<volume>78</volume>(<issue>3</issue>):<fpage>167</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr4-0897190012465950">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cundiff</surname>
<given-names>DK</given-names>
</name>
</person-group>. <article-title>A systematic review of Cochrane anticoagulation reviews</article-title>. <source>Medscape J Med</source>. <year>2009</year>;<volume>11</volume>(<issue>1</issue>):<fpage>5</fpage>.</citation>
</ref>
<ref id="bibr5-0897190012465950">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dobesh</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Stacy</surname>
<given-names>ZA</given-names>
</name>
</person-group>. <article-title>Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients</article-title>. <source>J Manag Care Pharm</source>. <year>2005</year>;<volume>11</volume>(<issue>9</issue>):<fpage>755</fpage>–<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr6-0897190012465950">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holbrook</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schulman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Witt</surname>
<given-names>DM</given-names>
</name>
<etal/>
</person-group> <article-title>Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines</article-title>. <source>Chest</source>. <year>2012</year>;<volume>141</volume>(<issue>2 suppl</issue>):<fpage>e152S</fpage>–<lpage>e184S</lpage>.</citation>
</ref>
<ref id="bibr7-0897190012465950">
<label>7</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Wolfram</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Matthias</surname>
<given-names>R</given-names>
</name>
</person-group>. <source>Regulation of Tissue Factor Expression</source>. <publisher-loc>Austin, TX</publisher-loc>: <publisher-name>Landes Bioscience and Springer Science+Business Media</publisher-name>; <year>2000</year>.</citation>
</ref>
<ref id="bibr8-0897190012465950">
<label>8</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Rolando</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Perumal</surname>
<given-names>T</given-names>
</name>
</person-group>. <source>Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis</source>. <publisher-loc>San Rafael, CA</publisher-loc>: <publisher-name>Morgan &amp; Claypool Life Sciences</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr9-0897190012465950">
<label>9</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Philip</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>George</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>PM</given-names>
</name>
<etal/>
</person-group> <source>Anticoagulant, Thrombolytic, and Antiplatelet Drugs</source>. <edition>IX ed</edition>., <year>1996</year>.</citation>
</ref>
<ref id="bibr10-0897190012465950">
<label>10</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Dipiro</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Talbert</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Yee</surname>
<given-names>GC</given-names>
</name>
<etal/>
</person-group> <source>Pharmacotherapy: A Pathophysiologic Approach</source>. <edition>8th ed</edition>., <year>2006</year>.</citation>
</ref>
<ref id="bibr11-0897190012465950">
<label>11</label>
<citation citation-type="journal">
<article-title>Preventing errors relating to commonly used anticoagulants</article-title>. <source>Sentinel Event Alert</source>. <year>2008</year>;(<issue>41</issue>):<fpage>1</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr12-0897190012465950">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desai</surname>
<given-names>UR</given-names>
</name>
</person-group>. <article-title>New antithrombin-based anticoagulants</article-title>. <source>Med Res Rev</source>. <year>2004</year>;<volume>24</volume>(<issue>2</issue>):<fpage>151</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr13-0897190012465950">
<label>13</label>
<citation citation-type="other">
<comment>Lexi-Comp OnlineTM Lexi-Comp Inc</comment>.</citation>
</ref>
<ref id="bibr14-0897190012465950">
<label>14</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Longo</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Fauci</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Kasper</surname>
<given-names>DL</given-names>
</name>
<etal/>
</person-group> <source>Harrison's Principles of Internal Medicine</source>. <edition>18 ed</edition>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>The McGraw Hill Company</publisher-name>.</citation>
</ref>
<ref id="bibr15-0897190012465950">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kroegel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reissig</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis</article-title>. <source>Respiration</source>. <year>2003</year>;<volume>70</volume>(<issue>1</issue>):<fpage>7</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr16-0897190012465950">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hacke</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kaste</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bluhmki</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>(<issue>13</issue>):<fpage>1317</fpage>–<lpage>1329</lpage>.</citation>
</ref>
<ref id="bibr17-0897190012465950">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guyatt</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Albers</surname>
<given-names>GW</given-names>
</name>
<etal/>
</person-group> <article-title>Executive summary: American college of chest physicians evidence-based clinical practice guidelines (8th edition)</article-title>. <source>Chest</source>. <year>2008</year>;<volume>133</volume>(<fpage>6</fpage> suppl):<fpage>71S</fpage>–<lpage>109S</lpage>.</citation>
</ref>
<ref id="bibr18-0897190012465950">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geerts</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Pineo</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Heit</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group> <article-title>Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy</article-title>. <source>Chest</source>. <year>2004</year>;<volume>126</volume>(<issue>3 suppl</issue>):<fpage>338S</fpage>–<lpage>400S</lpage>.</citation>
</ref>
<ref id="bibr19-0897190012465950">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nutescu</surname>
<given-names>EA</given-names>
</name>
</person-group>. <article-title>Assessing, preventing, and treating venous thromboembolism: evidence-based approaches</article-title>. <source>Am J Health Syst Pharm</source>. <year>2007</year>;<volume>64</volume>(<issue>11 suppl 7</issue>):<fpage>S5</fpage>–<lpage>S13</lpage>.</citation>
</ref>
<ref id="bibr20-0897190012465950">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Shaughnessy</surname>
<given-names>SG</given-names>
</name>
<etal/>
</person-group>. <article-title>Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety</article-title>. <source>Chest</source>. <year>2001</year>;<volume>119</volume>(<issue>1 suppl</issue>):<fpage>64S</fpage>–<lpage>94S</lpage>.</citation>
</ref>
<ref id="bibr21-0897190012465950">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nugent</surname>
<given-names>MA</given-names>
</name>
</person-group>: <article-title>Chemistry &amp; Biology of Heparin and Heparan sulfate</article-title>, <year>2005</year>.</citation>
</ref>
<ref id="bibr22-0897190012465950">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Baglin</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Weitz</surname>
<given-names>JI</given-names>
</name>
<etal/>
</person-group> <article-title>Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</article-title>. <source>Chest</source>. <year>2012</year>;<volume>141</volume>(<issue>2 suppl</issue>):<fpage>e24S</fpage>–<lpage>e43S</lpage>.</citation>
</ref>
<ref id="bibr23-0897190012465950">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Zumberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy</article-title>. <source>J Pharm Pract</source>. <year>2010</year>;<volume>23</volume>(<issue>3</issue>):<fpage>210</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr24-0897190012465950">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guervil</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Winterstein</surname>
<given-names>AG</given-names>
</name>
<etal/>
</person-group> <article-title>Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion</article-title>. <source>Ann Pharmacother</source>. <year>2011</year>;<volume>45</volume>(<issue>7-8</issue>):<fpage>861</fpage>–<lpage>868</lpage>.</citation>
</ref>
<ref id="bibr25-0897190012465950">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tahir</surname>
<given-names>R.</given-names>
</name>
</person-group> <article-title>A Review of unfractionated heparin and its monitoring</article-title>. <source>US Pharm</source>. <year>2007</year>;<volume>32</volume>:<fpage>HS26</fpage>–<lpage>HS36</lpage>.</citation>
</ref>
<ref id="bibr26-0897190012465950">
<label>26</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE.</given-names>
</name>
</person-group> <article-title>Heparin-induced thrombocytopenia</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Ginsberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kearon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
</person-group>, ed. <source>Critical Decisions in Thrombosis and hemostasis</source>.: <publisher-name>B.C. Decker Inc</publisher-name>.,; <year>1998</year>.</citation>
</ref>
<ref id="bibr27-0897190012465950">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Aird</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Rand</surname>
<given-names>JH</given-names>
</name>
</person-group>. <article-title>Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome</article-title>. <source>Hematology Am Soc Hematol Educ Program</source>. <year>2003</year>:<fpage>497</fpage>–<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr28-0897190012465950">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Juhl</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<etal/>
</person-group> <article-title>Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings</article-title>. <source>J Thromb Haemost</source>. <year>2006</year>;<volume>4</volume>(<issue>4</issue>):<fpage>759</fpage>–<lpage>765</lpage>.</citation>
</ref>
<ref id="bibr29-0897190012465950">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>MN</given-names>
</name>
</person-group>. <article-title>Low molecular weight heparin</article-title>. <source>Blood</source>. <year>1992</year>;<volume>79</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr30-0897190012465950">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guyatt</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Akl</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Crowther</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</article-title>. <source>Chest</source>. <year>2012</year>;<volume>141</volume>(<issue>2 suppl</issue>):<fpage>7S</fpage>–<lpage>47S</lpage>.</citation>
</ref>
<ref id="bibr31-0897190012465950">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>RI</given-names>
</name>
<etal/>
</person-group> <article-title>Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>349</volume>(<issue>2</issue>):<fpage>146</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr32-0897190012465950">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linkins</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Dans</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Moores</surname>
<given-names>LK</given-names>
</name>
<etal/>
</person-group> <article-title>Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</article-title>. <source>Chest</source>. <year>2012</year>;<volume>141</volume>(<issue>2 suppl</issue>):<fpage>e495S</fpage>–<lpage>e530S</lpage>.</citation>
</ref>
<ref id="bibr33-0897190012465950">
<label>33</label>
<citation citation-type="book">
<collab collab-type="author">Lovenox (enoxaparin) [package insert]</collab>. <publisher-loc>Bridgewater, NJ</publisher-loc>: <publisher-name>Sanofi Aventis</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr34-0897190012465950">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cockcroft</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Gault</surname>
<given-names>MH</given-names>
</name>
</person-group>. <article-title>Prediction of creatinine clearance from serum creatinine</article-title>. <source>Nephron</source>. <year>1976</year>;<volume>16</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr35-0897190012465950">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nutescu</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Spinler</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Wittkowsky</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings</article-title>. <source>Ann Pharmacother</source>. <year>2009</year>;<volume>43</volume>(<issue>6</issue>):<fpage>1064</fpage>–<lpage>1083</lpage>.</citation>
</ref>
<ref id="bibr36-0897190012465950">
<label>36</label>
<citation citation-type="book">
<collab collab-type="author">Fragmin (dalteparin) [package insert]</collab>. <publisher-loc>New York City, NY</publisher-loc>: <publisher-name>Pfizer</publisher-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr37-0897190012465950">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>New anticoagulants</article-title>. <source>Am Heart J</source>. <year>2001</year>;<volume>142</volume>(<issue>2 suppl</issue>):<fpage>S3</fpage>–<lpage>S8</lpage>.</citation>
</ref>
<ref id="bibr38-0897190012465950">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dalen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>DR</given-names>
</name>
<etal/>
</person-group> <article-title>Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range</article-title>. <source>Chest</source>. <year>2001</year>;<volume>119</volume>(<fpage>1</fpage> suppl):<fpage>8S</fpage>–<lpage>21S</lpage>.</citation>
</ref>
<ref id="bibr39-0897190012465950">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nutescu</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Bathija</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>LK</given-names>
</name>
<etal/>
</person-group> <article-title>Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption</article-title>. <source>Pharmacotherapy</source>. <year>2011</year>;<volume>31</volume>(<issue>12</issue>):<fpage>1161</fpage>–<lpage>1174</lpage>.</citation>
</ref>
<ref id="bibr40-0897190012465950">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>du Breuil</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Umland</surname>
<given-names>EM</given-names>
</name>
</person-group>. <article-title>Outpatient management of anticoagulation therapy</article-title>. <source>Am Fam Physician</source>. <year>2007</year>;<volume>75</volume>(<issue>7</issue>):<fpage>1031</fpage>–<lpage>1042</lpage>.</citation>
</ref>
<ref id="bibr41-0897190012465950">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Alamino</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Alonso-Coello</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Self-monitoring and self-management of oral anticoagulation</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2010</year>;(<issue>4</issue>):<fpage>CD003839</fpage>.</citation>
</ref>
<ref id="bibr42-0897190012465950">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bloomfield</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Greer</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes</article-title>. <source>Ann Intern Med</source>. <year>2011</year>;<volume>154</volume>(<issue>7</issue>):<fpage>472</fpage>–<lpage>482</lpage>.</citation>
</ref>
<ref id="bibr43-0897190012465950">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heneghan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Alonso-Coello</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Garcia-Alamino</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group> <article-title>Self-monitoring of oral anticoagulation: a systematic review and meta-analysis</article-title>. <source>Lancet</source>. <year>2006</year>;<volume>367</volume>(<issue>9508</issue>):<fpage>404</fpage>–<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr44-0897190012465950">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Warfarin therapy: tips and tools for better control</article-title>. <source>J Fam Pract</source>. <year>2011</year>;<volume>60</volume>(<issue>2</issue>):<fpage>70</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr45-0897190012465950">
<label>45</label>
<citation citation-type="other">
<comment>Clinicaltrials.gov: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate</comment>, <year>2005</year>.</citation>
</ref>
<ref id="bibr46-0897190012465950">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cotton</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>McCarthy JJHolcomb</surname>
<given-names>JB</given-names>
</name>
</person-group>. <article-title>Acutely injured patients on dabigatran</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>21</issue>):<fpage>2039</fpage>–<lpage>2040</lpage>.</citation>
</ref>
<ref id="bibr47-0897190012465950">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eerenberg</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Kamphuisen</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Sijpkens</surname>
<given-names>MK</given-names>
</name>
<etal/>
</person-group> <article-title>Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>124</volume>(<issue>14</issue>):<fpage>1573</fpage>–<lpage>1579</lpage>.</citation>
</ref>
<ref id="bibr48-0897190012465950">
<label>48</label>
<citation citation-type="book">
<collab collab-type="author">Pradaxa (dabigatran) [package insert]</collab>. <publisher-loc>Ridgefield, CT</publisher-loc>: <publisher-name>Boehringer Ingelheim</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr49-0897190012465950">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakkar</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Brenner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>OE</given-names>
</name>
<etal/>
</person-group> <article-title>Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>372</volume>(<issue>9632</issue>):<fpage>31</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr50-0897190012465950">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eriksson</surname>
<given-names>BI</given-names>
</name>
<name>
<surname>Borris</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group> <article-title>Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>(<issue>26</issue>):<fpage>2765</fpage>–<lpage>2775</lpage>.</citation>
</ref>
<ref id="bibr51-0897190012465950">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lassen</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Ageno</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Borris</surname>
<given-names>LC</given-names>
</name>
<etal/>
</person-group> <article-title>Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>(<issue>26</issue>):<fpage>2776</fpage>–<lpage>2786</lpage>.</citation>
</ref>
<ref id="bibr52-0897190012465950">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Rivaroxaban versus warfarin in nonvalvular atrial fibrillation</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>10</issue>):<fpage>883</fpage>–<lpage>891</lpage>.</citation>
</ref>
<ref id="bibr53-0897190012465950">
<label>53</label>
<citation citation-type="book">
<collab collab-type="author">Argatroban [package insert]</collab>. <publisher-loc>Research Triangle Park, NC</publisher-loc>: <publisher-name>Glaxo Smithkline</publisher-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr54-0897190012465950">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiser</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Burch</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Klem</surname>
<given-names>PM</given-names>
</name>
<etal/>
</person-group> <article-title>Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia</article-title>. <source>Pharmacotherapy</source>. <year>2008</year>;<volume>28</volume>(<issue>9</issue>):<fpage>1115</fpage>–<lpage>1124</lpage>.</citation>
</ref>
<ref id="bibr55-0897190012465950">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kushner</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Hand</surname>
<given-names>M</given-names>
</name>
</person-group>, <article-title>Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>54</volume>(<issue>23</issue>):<fpage>2205</fpage>–<lpage>2241</lpage>.</citation>
</ref>
<ref id="bibr56-0897190012465950">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bittl</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Chaitman</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Feit</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group> <article-title>Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study</article-title>. <source>Am Heart J</source>. <year>2001</year>;<volume>142</volume>(<issue>6</issue>):<fpage>952</fpage>–<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr57-0897190012465950">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stone</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>White</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</name>
<etal/>
</person-group> <article-title>Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>369</volume>(<issue>9565</issue>):<fpage>907</fpage>–<lpage>919</lpage>.</citation>
</ref>
<ref id="bibr58-0897190012465950">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Antman</surname>
<given-names>EM</given-names>
</name>
<etal/>
</person-group> <article-title>ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>(<issue>7</issue>):<fpage>e1</fpage>–<lpage>e157</lpage>.</citation>
</ref>
<ref id="bibr59-0897190012465950">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stone</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>McLaurin</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>DA</given-names>
</name>
<etal/>
</person-group> <article-title>Bivalirudin for patients with acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>355</volume>(<issue>21</issue>):<fpage>2203</fpage>–<lpage>2216</lpage>.</citation>
</ref>
<ref id="bibr60-0897190012465950">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsu</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Dager</surname>
<given-names>WE</given-names>
</name>
</person-group>. <article-title>Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia</article-title>. <source>Ann Pharmacother</source>. <year>2011</year>;<volume>45</volume>(<issue>10</issue>):<fpage>1185</fpage>–<lpage>1192</lpage>.</citation>
</ref>
<ref id="bibr61-0897190012465950">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baroletti</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Goldhaber</surname>
<given-names>SZ</given-names>
</name>
</person-group>. <article-title>Heparin-induced thrombocytopenia</article-title>. <source>Circulation</source>. <year>2006</year>;<volume>114</volume>(<issue>8</issue>):<fpage>e355</fpage>–<lpage>e356</lpage>.</citation>
</ref>
<ref id="bibr62-0897190012465950">
<label>62</label>
<citation citation-type="web">
<ext-link ext-link-type="uri" xlink:href="http://www.ouhsc.edu/platelets/Platelets/platelets%20publication.html">http://www.ouhsc.edu/platelets/Platelets/platelets%20publication.html</ext-link>; <comment>Platelets on the Web. Department of Biostatistics &amp; Epidemiology, College of Public Health, OUHSC; Vol. 2012</comment>. </citation>
</ref>
</ref-list>
</back>
</article>